NASDAQ, NKTR - Nektar Therapeutics
We are a biopharmaceutical company that develops and enables differentiated
therapeutics with our leading PEGylation and pulmonary drug development
technology platforms. Our mission is to create differentiated, innovative
products by applying our platform technologies to established or novel
medicines. By doing so, we aim to raise the standards of current patient care by
improving one or more performance parameters, including efficacy, safety or ease
of use. Ten products using these technology platforms have received regulatory
approval in the U.S. or Europe. Our two technology platforms are the basis of
nearly all of our partnered and proprietary product and product candidates.
We create or enable potential breakthrough products in two ways. First, we
develop products in collaboration with pharmaceutical and biotechnology
companies that seek to improve and differentiate their products. ...
Read SEC Filing on NASDAQ.com »